| Literature DB >> 31364553 |
B Devleesschauwer1, S M Pires2, I Young3, A Gill4, S E Majowicz5.
Abstract
Shiga toxin-producing Escherichia coli (STEC) infections are a significant public health issue, with foodborne transmission causing >1 million illnesses worldwide each year. We conducted a systematic review and meta-analysis (PROSPERO registry # CRD42017074239), to determine the relative association of different food types with sporadic illnesses caused by STEC. Searches were conducted from 01 August to 30 September 2017, using bibliographic and grey literature databases, websites and expert consultation. We identified 22 case-control studies of sporadic STEC infection in humans, from 10 countries within four World Health Organization subregions, from 1985 to 2012. We extracted data from 21 studies, for 237 individual measures in 11 food categories and across three status types (raw or undercooked, not raw and unknown). Beef was the most significant food item associated with STEC illness in the Americas and Europe, but in the Western Pacific region, chicken was most significant. These findings were not significantly moderated by the raw or cooked status of the food item, nor the publication year of the study. Data from the African, South-East Asian and Eastern Mediterranean subregions were lacking and it is unclear whether our results are relevant to these regions.Entities:
Keywords: Epidemiology; Shiga-like toxin-producing E. coli; food-borne infections; gastroenteritis
Year: 2019 PMID: 31364553 PMCID: PMC6625202 DOI: 10.1017/S0950268819001183
Source DB: PubMed Journal: Epidemiol Infect ISSN: 0950-2688 Impact factor: 2.451
Fig. 1.PRISMA diagram showing the results of the search for case-control studies of sporadic STEC infections in humans (all dates and locations).
Characteristics of the 22 case-control studies of non-outbreak (i.e. sporadic) STEC infection in humans, ordered by study timeframe (oldest to newest)
| Lead author (Year published) | Country (WHO subregion | Study timeframe | Study Pop. Age | Study Pop. Type | No. cases; no. controls | Types of cases (all lab. confirmed?) | Secondary cases included/ excluded | Case finding method | Control type | STEC category | Lab. methods adequate to identify STEC? |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MacDonald (1988) | USA (AMR A) | 1985–1986 | All | Patients of specific facilities | 24; 48 | Non-outbreak GI illness with positive lab. result (yes) | Included (1 of the 24 cases was secondary) | Active case finding (at laboratory level) | Facility/ practice | O157 | Yes (confirmed STEC O157:H7) |
| Bryant (1989) | Canada (AMR A) | 1986–1987 | All | Patients of specific facilities | 81; 96 | Non-outbreak GI illness with positive lab. result (yes) | Not described | Active case finding (in ER) | Friends | O157 | Yes (confirmed STEC O157) |
| Le Saux (1993) | Canada (AMR A) | 1990 | All | General pop. | 110; 220 | Non-outbreak positive lab. result (yes) | Excluded | Active case finding (at laboratory level) | Neighbours | O157 | Yes (confirmed STEC O157:H7) |
| Rowe (1993) | Canada (AMR A) | 1990 | Children (0–14 years) | Patients of specific facilities | 34; 102 | Post-diarrhoea cases of HUS (no; 88% were + for VTEC) | Not described | Active case finding (by physicians) | Facility/ practice | STEC | Yes (confirmed STEC) |
| Slutsker (1998) | USA (AMR A) | 1990–1992 | All | Patients of specific facilities | 73; 142 | Non-outbreak GI illness with positive lab. result (yes) | Not described | Active case finding (at laboratory level) | Facility/ practice | O157 | Yes (confirmed STEC O157) |
| Holton (1999) | Canada (AMR A) | 1991 | All | General pop. | 100; 200 | Non-outbreak GI illness with positive lab. result (yes) | Not described | Lab.-based surveillance with public health notification | Neighbours | O157 | Yes (confirmed STEC O157:H7) |
| Finelli (1995) | USA (AMR A) | 1994 | All | General pop. | 23; 46 | Non-outbreak GI illness with positive lab. result (yes) | Not described | Lab.-based surveillance with public health notification | Inadequately described | O157 | Inadequately described |
| Mead (1997) | USA (AMR A) | 1994 | All | General pop. | 22; 45 | Non-outbreak GI illness with positive lab. result (yes) | Excluded | Active case finding (at laboratory level) | Population | O157 | Yes (confirmed STEC O157:H7) |
| Parry (1998) | UK (EUR A) | 1994–1996 | All | General pop. | 85; 142 | Non-outbreak GI illness with positive lab. result (yes) | Excluded | Active case finding (at laboratory level) | Facility/ practice | O157 | Yes (confirmed STEC O157) |
| O'Brien (2001) | UK (EUR A) | 1996–1997 | All | General pop. | 369; 511 | Non-outbreak GI illness with positive lab. result (yes) | Excluded | Active case finding (at laboratory level) | Facility/ practice | O157 | Yes (confirmed STEC O157) |
| Kassenborg (2004) | USA (AMR A) | 1996–1997 | All | General pop. | 196; 372 | Non-outbreak GI illness with positive lab. result (yes) | Excluded | Active case finding (at laboratory level) | Population | O157 | Yes (confirmed STEC O157) |
| Piérard (1999) | Belgium (EUR A) | Inadequately described; 1990′s | All | Patients of specific facilities | 37; 69 | Non-outbreak GI illness, or HUS, with positive lab. result (yes) | Not described | Active case finding (at laboratory level) | Facility/practice | STEC | Yes (confirmed STEC) |
| Locking (2001) | UK (EUR A) | 1996–1999 | All | General pop. | 183; 545 | Non-outbreak GI illness, or HUS, with positive lab. result (yes) | Excluded | Lab.-based surveillance with public health notification | Facility/ practice | O157 | Yes (confirmed STEC O157) |
| Voetsch (2007) | USA (AMR A) | 1999–2000 | All | General pop. | 283; 534 | Non-outbreak GI illness with positive lab. result (yes) | Excluded | Active case finding (at laboratory level) | Population | O157 | Yes (confirmed STEC O157) |
| Vaillant(2009) | France (EUR A) | 2000–2001 | Children (0–15 years) | General pop. | 61; 114 | Post-diarrhoeal HUS with confirmation of STEC (yes) | Not described | HUS surveillance with public health notification | Facility/ practice | STEC | Yes (confirmed STEC) |
| Rivas (2008) | Argentina (AMR B) | 2001–2002 | Children (0–15 years) | Patients of specific facilities | 150; 299 | Non-outbreak GI illness, or HUS, with positive lab. result (yes); also post-diarrhoeal HUS (no) | Not described | Health record review | Neighbours | O157 | Yes (confirmed STEC O157) |
| Werber (2007) | Germany (EUR A) | 2001–2003 | All | General pop. | 202; 202 | Non-outbreak GI illness, or HUS, with positive lab. result (yes) | Not described | Lab.-based surveillance with public health notification | Population | STEC | Yes (confirmed STEC) |
| Hundy (2004) | Australia (WPR A) | 2002 | All | General pop. | 11; 22 | Non-outbreak illness/blood in stool with positive lab result (no) | Excluded | Lab.-based surveillance with public health notification | Population | STEC | Yes (presumptive STEC) |
| Denno (2009) | USA (AMR A) | 2003–2005 | Children (0–19 years) | General pop. | 39; 75 | Non-outbreak GI illness with positive lab. result (yes) | Excluded | Lab.-based surveillance with public health notification | Practice/ facility | O157 | Yes (confirmed STEC O157) |
| McPherson (2009) | Australia (WPR A) | 2003–2007 | All | General pop. | 113; 304 | Non-outbreak GI illness with positive lab. result (yes) | Excluded | Lab.-based surveillance with public health notification | Population | STEC | Yes (confirmed STEC) |
| Friesema (2015) | The Netherlands (EUR A) | 2008–2012 | All | General pop. | 208; 1563 | Non-outbreak GI illness with positive lab. result (yes) | Excluded | Lab.-based surveillance with public health notification | Population | STEC | Yes (confirmed STEC) |
| Jaros (2013) | New Zealand (WPR A) | 2011–2012 | All | General pop. | 113; 506 | Non-outbreak GI illness, or HUS, with positive lab. result (yes) | Excluded | Lab.-based surveillance with public health notification | Population | STEC O157 | Yes (confirmed STEC) |
WHO Subregions comprise the following countries: Region of the Americas A (AMR A): Canada, Cuba, USA.
Region of the Americas B (AMR B): Antigua and Barbuda, Argentina, Bahamas, Barbados, Belize, Brazil, Chile, Colombia, Costa Rica, Dominica, Dominican Republic, El Salvador, Grenada, Guyana, Honduras, Jamaica, Mexico, Panama, Paraguay, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Trinidad and Tobago, Uruguay, Venezuela (Bolivarian Republic of).
European Region A (EUR A): Andorra, Austria, Belgium, Croatia, Cyprus, Czech Republic, Denmark, Finland, France, Germany, Greece, Iceland, Ireland, Israel, Italy, Luxembourg, Malta, Monaco, Netherlands, Norway, Portugal, San Marino, Slovenia, Spain, Sweden, Switzerland, United Kingdom of Great Britain and Northern Ireland.
Western Pacific Region A (WPR A): Australia, Brunei Darussalam, Japan, New Zealand, Singapore.
Fig. 2.Study locations and timeframes for the 22 identified case-control studies of sporadic STEC infections in humans.
Selected risk of bias assessment indicators for the 22 case-control studies of non-outbreak (i.e. sporadic) STEC infection in humans, ordered by study timeframe (oldest to newest)
| Lead author (Year published) | Country (WHO subregion) | Study timeframe | Exposure window: cases | Exposure window: controls | Non-response rate and non-respondents | Robins- |
|---|---|---|---|---|---|---|
| MacDonald (1988) | USA (AMR A) | 1985–1986 | 7 days before illness | 7 days before interview | Not described | Serious |
| Bryant (1989) | Canada (AMR A) | 1986–1987 | 7 days before illness | Same calendar dates as case | Same non-response rate for cases and controls | Serious |
| Le Saux (1993) | Canada (AMR A) | 1990 | 10 days before illness | Same calendar dates as case | Not described | Moderate, towards null |
| Rowe (1993) | Canada (AMR A) | 1990 | 14 days before illness | 14 days before interview | Not described | Serious |
| Slutsker (1998) | USA (AMR A) | 1990–1992 | 7 days before illness | 7 days before interview | Not described | Moderate, towards null |
| Holton (1999) | Canada (AMR A) | 1991 | 7 days before illness | Same calendar dates as case | Not described | Moderate, towards null |
| Finelli (1995) | USA (AMR A) | 1994 | 7 days before illness | Not reported | Not described | No information |
| Mead (1997) | USA (AMR A) | 1994 | 7 days before illness | Same calendar dates as case | Different non-response rates for cases versus controls, with non-respondents described | Moderate, towards null |
| Parry (1998) | UK (EUR A) | 1994–1996 | 7 days before illness | Same calendar dates as case | Not described | Low |
| O'Brien (2001) | UK (EUR A) | 1996–1997 | 5 days before illness | Same calendar dates as case | Different non-response rates for cases versus controls, with non-respondents not described | Low |
| Kassenborg (2004) | USA (AMR A) | 1996–1997 | 5 days before illness | 5 days before interview | Not described | Low |
| Piérard (1999) | Belgium (EUR A) | Inadequately described; 1990′s | 14 days before illness | 14 days before interview | Not described | Moderate, towards null |
| Locking (2001) | UK (EUR A) | 1996–1999 | 14 days before illness | Same calendar dates as case | Not described | Moderate, towards null |
| Voetsch (2007) | USA (AMR A) | 1999–2000 | 7 days before illness | Same calendar dates as case | Not described | Low |
| Vaillant (2009) | France (EUR A) | 2000–2001 | 7 days before illness | Same calendar dates as case | Not described | Moderate, towards null |
| Rivas (2008) | Argentina (AMR B) | 2001–2002 | 7 days before illness | Same calendar dates as case | Not described | Moderate, towards null |
| Werber (2007) | Germany (EUR A) | 2001–2003 | 10 days before illness | 10 days before interview | Different non-response rates for cases versus controls, with non-respondents not described | Low |
| Hundy (2004) | Australia (WPR A) | 2002 | 10 days before illness | 10 days before interview | Not described | Moderate, towards null |
| Denno (2009) | USA (AMR A) | 2003–2005 | 2–8 days before illness | 2–8 days before interview | Not described | Low |
| McPherson (2009) | Australia (WPR A) | 2003–2007 | 10 days before illness | 10 days before interview | Not described | Moderate, towards null |
| Friesema (2015) | The Netherlands (EUR A) | 2008–2012 | 7 days before illness | 7 days before interview | Not described | Moderate, towards null |
| Jaros (2013) | New Zealand (WPR A) | 2011–2012 | 14 days before illness | 14 days before interview | Different non-response rates for cases versus controls, with non-respondents described | Moderate, towards null |
Modified ROBINS-I categories:
1. low risk of bias in the reported OR's for food exposures.
2. moderate risk of bias in the reported OR's for food exposures, with the bias likely towards the null (i.e. towards an OR = 1).
3. moderate risk of bias in the reported OR's for food exposures, with the bias likely away from the null (i.e. away from an OR = 1).
4. serious risk of bias (either toward or away from the null): the study has some important problems.
5. critical risk of bias (either toward or away from the null): the study is too problematic to provide useful evidence.
6. no information.
Categories of the 245 food items extracted from the 21 case-control studies of non-outbreak (i.e. sporadic) STEC infection in humans, ranked in descending order by the number of food items per category
| Food category (no. items within category; no. studies) | Types of foods items within the category (no. items; no. studies) | Number of items by cooked or processed status of the food item | ||
|---|---|---|---|---|
| Raw or undercooked | Not raw (i.e. cooked, treated, pasteurized) | Unknown/ not reported | ||
| Beef (83; 18) | Hamburger/ground beef (34; 15), beef (31; 5), beef sausage (4; 1), steak (3; 3), beef juice (3; 1), beef salami (3; 1), beef soup (2; 1), corned beef (2; 1), roast beef (1; 1) | 35 | 1 | 47 |
| Meat – unspecified (62; 13) | Meat (16; 7), deli meat (11; 5), minced meat (10; 2), sausage (8; 3), meat pies/empanadas (6; 1), hot dogs (3; 3), meatballs (3; 2), doner kebab (3; 1), meat casserole (1; 1), salami (1; 1) | 14 | 10 | 38 |
| Produce (38; 11) | Vegetables (14; 7), fruits/vegetables (6; 3), juice (5; 3), carrots (2; 1), fruit (1; 1), berries (1; 1), apricots (1; 1), cataloupe (1; 1), lettuce (1; 1), peaches (1; 1), plums (1; 1), strawberries (1; 1), tomatoes (1; 1), watercress (1; 1), watermelon (1; 1) | 16 | - | 22 |
| Dairy (25; 9) | Cheese (14; 4), milk (7; 4), milk/dairy products (2; 2), butter (1; 1), cream (1; 1) | 11 | 2 | 12 |
| Chicken (10; 8) | Chicken (9; 8), sliced processed chicken (1; 1) | 1 | 1 | 8 |
| Seafood (8; 4) | Fish (3; 2), shellfish (3; 2), seafood (1; 1), fish/seafood (1; 1) | – | – | 8 |
| Pork (7; 5) | Pork (4; 3), ham (3; 2) | – | 7 | |
| Eggs (5; 2) | Eggs (5; 2) | – | – | 5 |
| Lamb (3; 1) | Lamb (3; 1) | – | – | 3 |
| Turkey (2; 2) | Turkey (2; 2) | – | – | 2 |
| Poultry/Game – unspecified (2; 2) | Poultry/game (1; 1), other poultry than chicken or turkey (1; 1) | – | – | 2 |
Results of the meta-analysis, showing pooled univariate odds ratios (ORs) per food category (significant values shown in bold), ranked in descending order by the number of food items in the category
| Food Category (no. items within category; no. studies with useable data) | Odds ratio (95% confidence interval) | Trim and Fill Method | |||||
|---|---|---|---|---|---|---|---|
| Odds ratio (95% confidence interval) | |||||||
| Beef (80 | 72 | ||||||
| Meat – unspecified (60 | 61 | 1.069 (0.894–1.279) | 0.463 | ||||
| Produce (38; 11) | 0.119 | 72 | |||||
| Dairy (23 | 0.319 | 70 | |||||
| Chicken (9 | 0.827 (0.377–1.814) | 0.636 | 0.517 | 0.358 | 83 | – | – |
| Seafood (8; 4) | 0.758 (0.457–1.256) | 0.282 | 0.902 | 0.905 | 75 | – | – |
| Pork (7; 5) | 1.032 (0.632–1.685) | 0.900 | 0.201 | 0.239 | 63 | – | – |
| Eggs (5; 2) | 0.504 | 0.483 | 0 | – | – | ||
| Lamb (3; 1) | 1.936 (0.582–6.441) | 0.282 | 0.072 | 0.333 | 45 | – | – |
| Turkey (2; 2) | 1.055 (0.085–13.102) | 0.967 | N/A | 1.000 | 65 | – | – |
| Poultry/Game – unspecified (2; 2) | N/A | 1.000 | 32 | – | – | ||
These numbers are less than in Table 3 because some food items as reported did not have sufficient useable data
These items remained significant when clustering by study was accounted for
Fig. 3.Forest plots of the log odds ratio (OR) of the risk of human STEC infection from beef (a) and meat-unspecified (b), showing the overall pooled OR together with the 95% confidence interval (CI); ordered from oldest (top) to newest (bottom) study.
Results of the meta-analysis for each World Health Organization (WHO) Sub- Region, showing pooled univariate odds ratios (ORs) per food category (significant values shown in bold)
| Food Category | WHO Subregion AMR A | WHO Subregion AMR B | WHO Subregion EUR A | WHO Subregion WPR A | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. items per category (No. studies) | OR (95% C.I.) | No. items per category (No. studies) | OR (95% C.I.) | No. items per category (No. studies) | OR (95% C.I.) | No. items per category (No. studies) | OR (95% C.I.) | |||||
| Beef | 22 (9) | 81% | 32 (1) | 69% | 19 (6) | 67% | 7 (2) | 1.243 (0.730–2.118) | 62% | |||
| Meat – unspecified | 9 (4) | 64% | 8 (1) | 25% | 38 (5) | 1.172 (0.988–1.391) | 36% | 5 (3) | 1.295 (0.891–1.882) | 0% | ||
| Produce | 9 (3) | 59% | 0 (–) | N/A | N/A | 17 (5) | 0.872 (0.658–1.158) | 52% | 12 (3) | 0.476 (0.188–1.206) | 89% | |
| Dairy | 1 (1) | 9.774 (0.981–97.360) | 0% | 0 (–) | N/A | N/A | 20 (7) | 69% | 2 (1) | 1.209 (0.695–2.101) | 0% | |
| Chicken | 4 (4) | 0% | 0 (–) | N/A | N/A | 2 (2) | 1.320 (0.170–10.273) | 91% | 3 (2) | 0% | ||
| Seafood | 2 (1) | 0.683 (0.417–1.118) | 0% | 0 (–) | N/A | N/A | 5 (2) | 0.932 (0.385–2.258) | 80% | 1 (1) | 0% | |
| Pork | 2 (2) | 1.430 (0.841–2.431) | 0% | 2 (1) | 1.107 (0.320–3.830) | 76% | 0 (–) | N/A | N/A | 3 (2) | 0% | |
| Eggs | 0 (–) | N/A | N/A | 0 (–) | N/A | N/A | 1 (1) | 0% | 4 (1) | 0% | ||
| Lamb | 0 (–) | N/A | N/A | 0 (–) | N/A | N/A | 3 (1) | 1.936 (0.582–6.441) | 45% | 0 (–) | N/A | N/A |
| Turkey | 1 (1) | 0.347 (0.069–1.755) | 0% | 0 (–) | N/A | N/A | 0 (–) | N/A | N/A | 1 (1) | 4.667 (0.374–58.248) | 0% |
| Poultry/Game – unspecified | 0 (–) | N/A | N/A | 0 (–) | N/A | N/A | 2 (2) | 32% | 0 (–) | N/A | N/A | |
WHO Subregions comprise the following countries:
Region of the Americas A (AMR A): Canada, Cuba, USA.
Region of the Americas B (AMR B): Antigua and Barbuda, Argentina, Bahamas, Barbados, Belize, Brazil, Chile, Colombia, Costa Rica, Dominica, Dominican Republic, El Salvador, Grenada, Guyana, Honduras, Jamaica, Mexico, Panama, Paraguay, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Trinidad and Tobago, Uruguay, Venezuela (Bolivarian Republic of).
European Region A (EUR A): Andorra, Austria, Belgium, Croatia, Cyprus, Czech Republic, Denmark, Finland, France, Germany, Greece, Iceland, Ireland, Israel, Italy, Luxembourg, Malta, Monaco, Netherlands, Norway, Portugal, San Marino, Slovenia, Spain, Sweden, Switzerland, United Kingdom of Great Britain and Northern Ireland.
Western Pacific Region A (WPR A): Australia, Brunei Darussalam, Japan, New Zealand, Singapore.
Using trim and fill method.
These items remained significant when clustering by the study was accounted for.
Results from the meta-regression analysis of the univariate moderating effects of study characteristics, by food category, with significant values shown in bold (food categories with <20 results are not shown)
| Study Characteristic (no. items; no. studies) | Characteristic level (no. items; no. studies) | OR | 95% C.I. | Adjusted | ||
|---|---|---|---|---|---|---|
| Beef ( | ||||||
| WHO subregion | AMR A (22; 9; reference) | – | – | – | 72% | 0% |
| AMR B (32; 1) | 1.121 | 0.732–1.717 | 0.600 | |||
| EUR A (19; 6) | 0.840 | 0.522–1.351 | 0.473 | |||
| WPR A (7; 2) | 0.714 | 0.368–1.385 | 0.319 | |||
| Publication year | (80; 18) | 1.019 | 0.995–1.044 | 0.128 | 71% | 4.7% |
| Study population age | All (37; 14; reference) | – | – | – | 71% | 1.5% |
| Adults (5; 2) | 1.327 | 0.689–2.552 | 0.397 | |||
| Children (38; 4) | 1.336 | 0.941–1.898 | 0.105 | |||
| Food item status | Not raw (1; 1; reference) | – | – | – | 54% | 55% |
| Raw or undercooked (33; 9) | 2.404 | 0.892–6.483 | 0.083 | |||
| Unknown (46; 14) | 1.036 | 0.387–2.776 | 0.944 | |||
| Robin's I | 1 (14; 4; reference) | – | – | – | 71% | 3.0% |
| 2 (61; 11) | 1.389 | 0.903–2.137 | 0.135 | |||
| 4 (4; 2) | 1.009 | 0.448–2.274 | 0.982 | |||
| 6 (1; 1) | 4.002 | 0.702–22.804 | 0.118 | |||
| Believeable findings | Yes (79; 17; reference) | – | – | – | 72% | 1.8% |
| No (1; 1) | 3.122 | 0.564–17.270 | 0.192 | |||
| Meat–unspecified ( | ||||||
| WHO subregion | AMR A (9; 4; reference) | – | – | – | 38% | 60% |
| AMR B (8; 1) | ||||||
| EUR A (38; 5) | 0.915 | 0.645–1.298 | 0.619 | |||
| WPR A (5; 3) | 0.866 | 0.488–1.537 | 0.624 | |||
| Publication year | (60; 13) | 0.999 | 0.978–1.021 | 0.935 | 62% | 0% |
| Study population age | All (24; 9; reference) | – | – | – | 58% | 11% |
| Adults (10; 2) | 1.453 | 0.940–2.246 | 0.093 | |||
| Children (26; 5) | 0.921 | 0.651–1.302 | 0.641 | |||
| Food item status | Not raw (10; 3; reference) | – | – | – | 59% | 5.5% |
| Raw or undercooked (13; 5) | 1.577 | 0.959–2.595 | 0.073 | |||
| Unknown (37; 11) | 1.266 | 0.825–1.941 | 0.280 | |||
| Robin's I | 1 (24; 2; reference) | – | – | – | 62% | 0% |
| 2 (29; 9) | 0.868 | 0.610–1.235 | 0.431 | |||
| 4 (7; 2) | 1.126 | 0.671–1.891 | 0.654 | |||
| 6 (0; 0) | N/A | N/A | N/A | |||
| Believeable findings | Yes (59; 12; reference) | – | – | – | 56% | 22% |
| No (1; 1) | ||||||
| Produce ( | ||||||
| WHO subregion | AMR A (9; 3; reference) | – | – | – | 65% | 21% |
| AMR B (0; 0) | N/A | N/A | N/A | |||
| EUR A (17; 5) | ||||||
| WPR A (12; 3) | 1.149 | 0.650–2.029 | 0.633 | |||
| Publication year | (38; 11) | 0.976 | 0.939–1.014 | 0.212 | 70% | 7.6% |
| Study population age | All (26; 9; reference) | – | – | – | 73% | 0% |
| Adults (4; 2) | 0.888 | 0.412–1.916 | 0.762 | |||
| Children (8; 3) | 1.077 | 0.585–1.982 | 0.812 | |||
| Food item status | Not raw (0; 0) | N/A | N/A | N/A | 72% | 0% |
| Raw or undercooked (16; 7; reference) | – | – | – | |||
| Unknown (22; 9) | 1.035 | 0.649–1.650 | 0.885 | |||
| Robin's I | 1 (12; 4; reference) | – | – | – | 71% | 2.2% |
| 2 (26; 7) | 0.841 | 0.523–1.352 | 0.475 | |||
| 4 (0; 0) | N/A | N/A | N/A | |||
| 6 (0; 0) | N/A | N/A | N/A | |||
| Believeable findings | Yes (38; 11; reference) | – | – | – | 72% | N/A |
| No (0; 0) | N/A | N/A | N/A | |||
| Dairy ( | ||||||
| WHO subregion | AMR A (1; 1; reference) | – | – | – | 66% | 22% |
| AMR B (0; 0) | N/A | N/A | N/A | |||
| EUR A (20; 7) | ||||||
| WPR A (2; 1) | 0.127 | 0.009–1.695 | 0.118 | |||
| Publication year | (23; 9) | 0.954 | 0.909–1.000 | 0.051 | 67% | 10% |
| Study population age | All (9; 5; reference) | – | – | – | 60% | 37% |
| Adults (3; 2) | 0.887 | 0.374–2.104 | 0.786 | |||
| Children (11; 4) | ||||||
| Food item status | Not raw (2; 2; reference) | N/A | N/A | N/A | 63% | 10% |
| Raw or undercooked (9; 6) | 1.183 | 0.485–2.887 | 0.711 | |||
| Unknown (12; 4) | 0.557 | 0.247–1.254 | 0.157 | |||
| Robin's I | 1 (7; 3; reference) | – | – | – | 69% | 1.2% |
| 2 (15; 5) | 0.638 | 0.350–1.163 | 0.143 | |||
| 4 (1; 1) | 10.040 | 0.789–127.810 | 0.076 | |||
| 6 (0; 0) | N/A | N/A | N/A | |||
| Believeable findings | Yes (22; 8; reference) | – | – | – | 68% | 12% |
| No (1; 1) | ||||||
These items remained significant when clustering by the study was accounted for.